4 Repeat Tauopathy Neuroimaging Initiative
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 45 - 90 |
| Updated: | 1/12/2019 |
| Start Date: | January 2011 |
| End Date: | February 2020 |
Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration
The purpose of this study is to evaluate several different tests, including brain imaging,
eye movement testing, body fluid samples, measurements of memory and other thinking
abilities, and measures of functional independence in the hope that this information can be
used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our
understanding of the biological causes of these diseases offer hope for new treatments. As
such treatments are developed, sensitive and specific biological measurements (biomarkers)
will be needed to provide precise and direct measures of the state of the brain, which will
improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance
Imaging (MRI) has previously been used to measure disease-related changes in the brain. The
goal of this study is to identify the best methods of analysis (including eye movements,
imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain
biomarkers in the blood and cerebrospinal fluid might also be useful for following these
diseases over time. This study will examine the value of blood and CSF biomarkers relative to
brain imaging and functional measures.
eye movement testing, body fluid samples, measurements of memory and other thinking
abilities, and measures of functional independence in the hope that this information can be
used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our
understanding of the biological causes of these diseases offer hope for new treatments. As
such treatments are developed, sensitive and specific biological measurements (biomarkers)
will be needed to provide precise and direct measures of the state of the brain, which will
improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance
Imaging (MRI) has previously been used to measure disease-related changes in the brain. The
goal of this study is to identify the best methods of analysis (including eye movements,
imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain
biomarkers in the blood and cerebrospinal fluid might also be useful for following these
diseases over time. This study will examine the value of blood and CSF biomarkers relative to
brain imaging and functional measures.
Inclusion Criteria:
- Clinical diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration
- Must have a reliable study partner who has frequent contact with the subject
- Willing and able to undergo testing procedures
Exclusion Criteria:
- Significant neurological disease other than PSP or CBD
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal
fragments or foreign objects in the eyes, skin or body
We found this trial at
1
site
San Francisco, California 94143
Principal Investigator: Adam L Boxer, MD, PhD
Phone: 415-476-9578
Click here to add this to my saved trials
